Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Chronic lymphocytic leukemia


Other Names for this Disease

  • CLL
  • Leukemia, lymphocytic, chronic
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Treatment

Management Guidelines

  • The Chronic Lymphocytic Leukemia Information Group provides information regarding the treatment of chronic lymphocytic leukemia and related complications. Click on the above links to access this information.

Clinical Trials & Research for this Disease

  • ClinicalTrials.gov lists trials that are studying or have studied Chronic lymphocytic leukemia. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.

Medical Products

The medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.


Generic Name Ofatumumab
Trade Name
(Manufacturer Name)
Arzerra
(GlaxoSmithKline)
Indication
The FDA has approved this product to be used in this manner.
Ofatumumab in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.
More Information about this product Drug Information Portal

Generic Name Alemtuzumab
Trade Name
(Manufacturer Name)
Campath®
(Genzyme Corporation)
Indication
The FDA has approved this product to be used in this manner.
The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy.
More Information about this product Drug Information Portal
Medline Plus Health Information

Generic Name Buffered intrathecal electrolyte/dextrose injection
Trade Name
(Manufacturer Name)
Elliotts B Solution
(QOL Medical, LLC)
Indication
The FDA has approved this product to be used in this manner.
For the intrathecal administration of methotrexate and cytarabine for the prevention or treatment of meningeal leukemia and lymphocytic lymphoma.
More Information about this product Drug Information Portal

Generic Name Fludarabine phosphate
Trade Name
(Manufacturer Name)
Fludara®
(Genzyme)
Indication
The FDA has approved this product to be used in this manner.
Treatment of chronic lymphocytic leukemia (CLL), including refractory CLL.
More Information about this product Drug Information Portal
Medline Plus Health Information

Generic Name Fludarabine phosphate oral tablets
Trade Name
(Manufacturer Name)
Fludarabine® (oral)
(Antisoma )
Indication
The FDA has approved this product to be used in this manner.
Treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) whose disease has not responded to or has progressed during or after treatment with at least one standard alkylating-agent containing regimen
More Information about this product Drug Information Portal

Generic Name obinutuzumab
Trade Name
(Manufacturer Name)
Gazyva
(Genentech, Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of patients with previously untreated chronic lymphocytic leukemia in combination with chlorambucil.
More Information about this product Drug Information Portal

Generic Name ibrutinib
Trade Name
(Manufacturer Name)
Imbruvica
(Pharmacyclics, Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
More Information about this product Drug Information Portal

Generic Name Bendamustine hydrochloride
Trade Name
(Manufacturer Name)
Treanda
(Cephalon® Oncology)
Indication
The FDA has approved this product to be used in this manner.
Treatment of patients with chronic lymphocytic leukemia
More Information about this product Drug Information Portal
Medline Plus Health Information

Other Names for this Disease
  • CLL
  • Leukemia, lymphocytic, chronic
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.